Cargando…
Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients
Objectives. To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA). Methods. Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under infliximab were included. None had dyslipoproteinemia or previous statin use....
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143445/ https://www.ncbi.nlm.nih.gov/pubmed/21804855 http://dx.doi.org/10.1155/2011/352686 |
_version_ | 1782208912837050368 |
---|---|
author | Castro, Karla R. Aikawa, Nádia E. Saad, Carla Gonçalves Moraes, Júlio C. B. Medeiros, Ana C. Mota, Licia Maria H. Silva, Clovis A. A. Bonfá, Eloísa Carvalho, Jozélio F. |
author_facet | Castro, Karla R. Aikawa, Nádia E. Saad, Carla Gonçalves Moraes, Júlio C. B. Medeiros, Ana C. Mota, Licia Maria H. Silva, Clovis A. A. Bonfá, Eloísa Carvalho, Jozélio F. |
author_sort | Castro, Karla R. |
collection | PubMed |
description | Objectives. To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA). Methods. Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under infliximab were included. None had dyslipoproteinemia or previous statin use. Total cholesterol (TC) and its fractions, inflammatory markers, and prednisone use were evaluated. Results. The comparisons of lipid levels between baseline and after three months (3M) of anti-TNF therapy showed that there was a significant increase in mean triglycerides (117.8 ± 49.7 versus 140.1 ± 64.1 mg/dL, P = 0.028) and VLDL-c (23.6 ± 10.5 versus 28.4 ± 13.7 mg/dL, P = 0.019) levels. In contrast, there were no differences in the mean TC (P = 0.28), LDL-c (P = 0.42), and HDL-c (P = 0.26) levels. Analysis of the frequencies of each lipid alteration at baseline and at 3M were alike (P > 0.05). Positive correlations were found between VLDL-c and CRP (r = 0.647, P = 0.009) and between triglycerides and CRP (r = 0.604, P = 0.017) levels at 3M. ESR reduction was observed after 3M (P = 0.04). Mean prednisone dose remained stable at beginning and at 3M (P = 0.37). Conclusion. This study demonstrated that anti-TNF may increase TG and VLDL-c levels in PsA patients after three months. |
format | Online Article Text |
id | pubmed-3143445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-31434452011-07-29 Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients Castro, Karla R. Aikawa, Nádia E. Saad, Carla Gonçalves Moraes, Júlio C. B. Medeiros, Ana C. Mota, Licia Maria H. Silva, Clovis A. A. Bonfá, Eloísa Carvalho, Jozélio F. Clin Dev Immunol Research Article Objectives. To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA). Methods. Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under infliximab were included. None had dyslipoproteinemia or previous statin use. Total cholesterol (TC) and its fractions, inflammatory markers, and prednisone use were evaluated. Results. The comparisons of lipid levels between baseline and after three months (3M) of anti-TNF therapy showed that there was a significant increase in mean triglycerides (117.8 ± 49.7 versus 140.1 ± 64.1 mg/dL, P = 0.028) and VLDL-c (23.6 ± 10.5 versus 28.4 ± 13.7 mg/dL, P = 0.019) levels. In contrast, there were no differences in the mean TC (P = 0.28), LDL-c (P = 0.42), and HDL-c (P = 0.26) levels. Analysis of the frequencies of each lipid alteration at baseline and at 3M were alike (P > 0.05). Positive correlations were found between VLDL-c and CRP (r = 0.647, P = 0.009) and between triglycerides and CRP (r = 0.604, P = 0.017) levels at 3M. ESR reduction was observed after 3M (P = 0.04). Mean prednisone dose remained stable at beginning and at 3M (P = 0.37). Conclusion. This study demonstrated that anti-TNF may increase TG and VLDL-c levels in PsA patients after three months. Hindawi Publishing Corporation 2011 2011-07-24 /pmc/articles/PMC3143445/ /pubmed/21804855 http://dx.doi.org/10.1155/2011/352686 Text en Copyright © 2011 Karla R. Castro et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Castro, Karla R. Aikawa, Nádia E. Saad, Carla Gonçalves Moraes, Júlio C. B. Medeiros, Ana C. Mota, Licia Maria H. Silva, Clovis A. A. Bonfá, Eloísa Carvalho, Jozélio F. Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients |
title | Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients |
title_full | Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients |
title_fullStr | Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients |
title_full_unstemmed | Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients |
title_short | Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients |
title_sort | infliximab induces increase in triglyceride levels in psoriatic arthritis patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143445/ https://www.ncbi.nlm.nih.gov/pubmed/21804855 http://dx.doi.org/10.1155/2011/352686 |
work_keys_str_mv | AT castrokarlar infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients AT aikawanadiae infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients AT saadcarlagoncalves infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients AT moraesjuliocb infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients AT medeirosanac infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients AT motaliciamariah infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients AT silvaclovisaa infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients AT bonfaeloisa infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients AT carvalhojozeliof infliximabinducesincreaseintriglyceridelevelsinpsoriaticarthritispatients |